In Brief: Ventritex
This article was originally published in The Gray Sheet
Ventritex: Begins U.S. clinical trials of its SPL single-wire transvenous lead system following receipt of an investigational device exemption from FDA. The SPL incorporates technology from Ventritex' dual-lead TVL transvenous lead, which was approved by FDA in May ("The Gray Sheet" May 20, I&W-1). An initial U.S. implant of the SPL was performed May 28 at St. Vincent Hospital in Indianapolis, Ventritex says...
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.